Try our mobile app

Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema

Published: 2021-03-29 11:05:00 ET
<<<  go to IONS company page

- IONIS-PKK-L Rx met its primary and all secondary endpoints, including a mean reduction of up to 97% in HAE attacks compared to placebo

CARLSBAD, Calif., March 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by patients with hereditary angioedema (HAE) compared to placebo. The study demonstrated a mean reduction of 90% in the number of monthly HAE attacks in weeks one to 17 of the study (p